ISSN: 2181-3906 2026

International scientific journal
«MODERN SCIENCE AND RESEARCH»
VOLUME 5 / ISSUE 3 / UIF:8.2 / MODERNSCIENCE.UZ

THE IMPORTANCE AND BENEFITS OF LEVOCARNITINE IN CHRONIC HEART FAILURE

Azim Odilov Jamil o'g'li
Choriyev akabur Anvarovich
Assistant.
Students at Asia International University. Bukhara, Uzbekistan.

https://doi.org/10.5281/zenodo.19053761

Abstract. *Chronic heart failure (CHF) is a condition characterized by the inability of the heart to pump sufficient blood to meet the metabolic needs of body tissues. This leads to symptoms such as dyspnea, fatigue, and fluid retention. Among the metabolic-supportive medications used in CHF management, levocarnitine has gained attention for its ability to enhance myocardial energy production and support cardiac metabolism. This paper discusses the mechanism, benefits, clinical role, and indications of levocarnitine in chronic heart failure.*

Keywords: *Chronic heart failure, Levocarnitine, mitochondrial function, myocardial energy metabolism.*

1. What is Levocarnitine?

Levocarnitine (L-carnitine) is a naturally occurring amino acid–like compound responsible for transporting long-chain fatty acids into the mitochondria, where they undergo β-oxidation to produce cellular energy.

In cardiac muscle—which highly depends on fatty acid oxidation—levocarnitine plays a crucial role in maintaining efficient myocardial energy production.

2. Role of Levocarnitine in Chronic Heart Failure

In **CHF,** impaired mitochondrial function reduces myocardial energy availability. This contributes to decreased contractility, worsening symptoms, and disease progression.

Levocarnitine supplementation improves mitochondrial fatty acid transport, enhances **ATP** generation, reduces toxic fatty **acyl-CoA accumulation**, and supports overall cardiac performance.

3. Benefits of Levocarnitine in Heart Failure

a. Improved Cardiac Energy Production

CHF patients often suffer from metabolic insufficiency. Levocarnitine boosts **ATP** generation within cardiomyocytes, helping the heart pump more efficiently.

b. Reduction in Symptoms

Levocarnitine improves exercise tolerance, reduces fatigue, and enhances daily functioning by supporting myocardial metabolism.

c. Cardioprotective Effects

Levocarnitine reduces oxidative stress, prevents lipid accumulation in cardiac cells, and supports myocardial recovery in **CHF**.

d. Reduced Hospitalization and Improved Outcomes

By improving myocardial efficiency and reducing metabolic stress, levocarnitine may decrease acute CHF exacerbations and the frequency of hospital admissions.

4. Levocarnitine in Combination with Other Medications

Levocarnitine complements standard **CHF** therapies such as **ACE inhibitors**, **beta-blockers**, **diuretics,** and **aldosterone antagonists**. Because it works through metabolic pathways rather than hemodynamic mechanisms, levocarnitine can be safely combined with most heart failure medications to improve therapeutic outcomes.

5. Indications and Usage

Levocarnitine is recommended for patients with:

- Chronic heart failure with symptoms of reduced exercise tolerance
- Carnitine deficiency
- Cardiomyopathy associated with metabolic disorders
- Ischemic heart disease with impaired energy metabolism

6. Side Effects and Considerations

Levocarnitine is generally safe and well-tolerated. Possible side effects include:

- Gastrointestinal discomfort **(nausea, vomiting**)
- Fish-like body **odor** (due to trimethylamine production)
- Rare allergic reactions

Monitoring is recommended in **renal insufficiency** due to altered excretion.

7. Conclusion

Levocarnitine serves as a valuable metabolic therapy in chronic heart failure by improving myocardial energetics, reducing oxidative stress, relieving symptoms, and potentially improving long-term outcomes. When used alongside standard CHF medications, levocarnitine enhances cardiac performance and supports a better quality of life for patients.

REFERENCES

1. Odilov Azim Jamil o’g’li (2025) THE IMPORTANCE AND BENEFITS OF IVABRADINE IN CHRONIC HEART FAILURE "NEW RENAISSANCE" International scientific journal international scientific journal volume Issue 5.
2. Jamshidovich, A. S. (2024). EFFECT OF ISMIZHEN DRUG ON BODY IMMUNITY. *Лучшие интеллектуальные исследования*, *15*(2), 132-137.
3. Jamshidovich, A. S. (2024). POSITIVE EFFECTS OF THE DRUG CARCIL. *Ta'lim innovatsiyasi va integratsiyasi*, *15*(3), 127-131.
4. Jamshidovich, A. S. (2024). РЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ КАВИНТОНА. *Ta'lim innovatsiyasi va integratsiyasi*, *15*(3), 132-136.
5. Jamshidovich, A. S. (2024). Современный Эффект Спрея Мометазон. *Research Journal of Trauma and Disability Studies*, *3*(3), 62-65.
6. Jamshidovich, A. S. (2024). THE ROLE OF" SIMONTE PLUS" DRUG IN THE MODERN TREATMENT OF BRONCHIAL ASTHMA. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(5), 66-70.
7. Jamshidovich, A. S. (2024). FEATURES OF THE BIOMECHANISM OF THE DRUG LEVOMYCETIN (CHLORAMPHENICOL). *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(9), 298-301.

8. Jamshidovich, A. S. (2024). THE MOST IMPORTANT INDICATORS OF OMEGA 3 SUBSTANCE IN THE METABOLISM OF THE HUMAN BODY. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(10), 113-117.
9. Komilovich, E. B., & Khalimovich, M. N. (2024). CARDIAC ISCHEMIA. ANGINA CLINICAL FORMS AND DIAGNOSIS. *Journal of new century innovations*, *46*(1), 70-78.
10. Komilovich, E. B. (2024). CORONARY HEART DISEASE. ANGINA EMERGENCY CARE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 235-242.
11. Komilovich, E. B. (2024). YURAK ISHEMIK KASALLIGI. STENOKARDIYANI DAVOLASHNING ZAMONAVIY TAMOYILLARI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(6), 3-11.
12. Jamshidovich, A. S. (2024). THE MOST IMPORTANT BENEFITS OF GINGER FOR THE HUMAN BODY'S IMMUNITY. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(11), 269-273.
13. Axmedov, S. (2024). THE SPECIFIC EFFECT OF THE DRUG" BAKLASAN" IN CEREBROVASCULAR DISEASES AND ITS PRACTICAL SIGNIFICANCE TODAY. *Modern Science and Research*, *3*(12), 485-492.
14. Komilovich, E. B. Z. (2023). Coronary Artery Disease. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *3*(12), 81-87.
15. Komilovich, E. B. (2024). CORONARY HEART DISEASE. ANGINA TREATMENT. *Journal of new century innovations*, *46*(1), 95-104.
16. Komilovich, E. B. (2024). HYPERTENSION TREATMENT. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 227-234.
17. Эргашов, Б. К. (2024). ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА. СТЕНОКАРДИЯ ПРОФИЛАКТИКА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(6), 21-31.
18. Axmedov, S. (2025). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА ЭСКУЗАН ПРИ СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ. *Modern Science and Research*, *4*(1), 380-387.
19. Эргашов, Б. К. (2024). ГИПЕРТОНИЧЕСКАЯ БОЛЕЗНЬ ДИАГНОСТИКА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(6), 70-78.
20. Komilovich, E. B. (2024). HYPERTENSION DIAGNOSTICS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(6), 42-49.
21. Xusenovich, M. S., & Turapjanovna, Z. M. (2024). SEMIZLIKNING TURLI FENOTIPLARDA KARDIOMETABOLIK XAVF OMILLARINI TAQQOSLASH. *SO ‘NGI ILMIY TADQIQOTLAR NAZARIYASI*, *7*(4), 112-116.
22. Husenovich, M. S., & Turabdjanovna, Z. M. (2024). STUDY OF DIURNAL PROFILE OF ARTERIAL HYPERTENSION IN DIFFERENT PHENOTYPE OBESITY. *образование наука и инновационные идеи в мире*, *43*(1), 129-131.
23. Xusenovich, M. S. (2024, September). SEMIZLIKNI TURLI FENOTIPLARIDA YURAK QON-TOMIR KASALLIKLARINI KELIB CHIQISH XAVFI PROGNOZI.

In *INTERNATIONAL SCIENTIFIC RESEARCH CONFERENCE* (Vol. 3, No. 26, pp. 15-18).

24. Xusenovich, M. S. (2024). O ‘ZBEKISTONDA RESPUBLIKASIDA YURAK-QON TOMIR KASALLIKLARI TARQALISHI VA HOZIRGI KUNDAGI KO’RILAYOTGAN CHORA TADBIRLAR. *AMERICAN JOURNAL OF SOCIAL SCIENCE*, *2*(3), 79-82.
25. Xusenovich, M. S., & Allayarovich, A. A. (2024). O ‘ZBEKISTONDA YURAK-QON TOMIR KASALLIKLARI TARQALISHI VA HOZIRGI KUNDAGI TENDENSIYASI. *MODELS AND METHODS FOR INCREASING THE EFFICIENCY OF INNOVATIVE RESEARCH*, *4*(38), 54-57.
26. Ravshanovna, X. L. (2021, June). MINIMALLY INVASIVE METHODS OF TREATMENT OF DENTAL CARIES IN ADULTS. In *" ONLINE-CONFERENCES" PLATFORM* (pp. 118-119).
27. Axmedov, S. (2025). SPECIFIC PROPERTIES OF ROXERA DRUG IN CARDIOVASCULAR DISEASES. *Modern Science and Research*, *4*(2), 472-479.
28. Axmedov, S. (2025). THE DRUG PHYSIOTENS, THE FEATURES OF THE DRUG AND ITS USE IN THE FIELD OF CARDIOLOGY, IN PATIENTS WITH HEAVY BODY WEIGHT. *Modern Science and Research*, *4*(3), 350-358.
29. Axmedov, S. (2025). THE USE OF MIRENA IN GYNECOLOGIC DISEASES AND ITS SIGNIFICANCE. *Modern Science and Research*, *4*(4), 304-312.
30. Axmedov, S. (2025). THE ROLE, FUNCTIONS AND IMPORTANCE OF GLUTAMIC ACID IN THE HUMAN BODY. *Modern Science and Research*, *4*(5).